Get started
Work

Abstract GS3-08: Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-gs3-08
Authors: K. L. Jhaveri, P. Neven, M. Casalnuovo, S. Kim, E. Tokunaga, P. Aftimos, C. Saura, J. O'Shaughnessy, N. Harbeck, L. A. Carey, G. Curigliano, J. Watanabe, E. Lim, J. Huang, Z. Qingyuan, A. Llombart-Cussac, C. Huang, B. Desai, X. Wang, S. Cao, F. Bidard, Y. Limay
Institutions: Memorial Sloan Kettering Cancer Center, Universitair Ziekenhuis Leuven, Asan Medical Center, University of Ulsan, National Hospital Organization Kyushu Cancer Center, Institut Jules Bordet, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, LMU Klinikum, Ludwig-Maximilians-Universität München, University of North Carolina at Chapel Hill, University of Milan, European Institute of Oncology, Juntendo University, Garvan Institute of Medical Research, UNSW Sydney, Central South University, Xiangya Hospital Central South University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Universidad Cardenal Herrera CEU, National Taiwan University, National Taiwan University Hospital, Eli Lilly (United States), Institut Curie
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129293397
Cites:
Cited by:
Related to: